This page shows the latest overactive bladder news and features for those working in and with pharma, biotech and healthcare.
The phase 3 EMPOWUR trial of vibegron in patients with incontinence caused by overactive bladder (OAB) showed that the beta-3 adrenergic agonist performed significantly better than placebo on the two
Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... There are no currently available FDA-approved gene therapy treatments for overactive bladder.
The proceeds will fund phase III trials of its overactive bladder treatment candidate vibegron, which it in-licensed last year from Merck &Co. ... Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB
overactive in depression. ... Aside from its use as a wrinkle treatment Botox is already approved to treat various medical conditions, including chronic migraine, excessive sweating and overactive bladder among others, and is Allergan's
Clinical trials are ongoing to test its application against overactive bladder and migraine.
The overarching aim is to prepare for the forthcoming patent expiries on big-selling drugs Vesicare (solifenacin succinate) for overactive bladder and cancer therapy Tarceva (erlotinib).
More from news
Approximately 4 fully matching, plus 44 partially matching documents found.
In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new
In addition to migraine and adult spasticity, its approved indications include overactive bladder, muscle stiffness in elbow, wrist and fingers, muscle problems in the eye, crow's feet lines and severe
For example, we are a GCL in urology; we have Vesicare, which has 40 per cent market share in the overactive bladder (OAB) market. ... From an OAB perspective, we support the Bladder and Bowel Foundation here in the UK, which provides a patient advice
As part of a national campaign called A Matter of Urgency’, the show-stopping garden was designed to raise awareness of Overactive Bladder which affects nearly one in five people in ... Nearly one in five people in the UK over 40 have an overactive
Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
His MSc project involved performing a health economic evaluation of the cost-effectiveness of different overactive bladder treatments available in the UK. ... The appointment of Trishal, with his specific expertise in visual science and overactive bladder
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...